Hu-Mik- Beta-1
Phase 1Biologic
Hu-Mik- Beta-1 is one of 83 biologic programs targeting Leukemia. It is currently in Phase 1.
3
Indications
3
Total Trials
0
Active Trials
82
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
508 competitors in Leukemia
#DrugCompanyPhaseTrials
1Cytoxan
BBaxter Healthcare Corporation
Phase 3
Fludara
SanofiPhase 3
Vepesid
AAvyxa
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Leukine
SanofiPhase 3
Busulfex
Akero TherapeuticsPhase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Mesnex
BBaxter Healthcare Corporation
Phase 3
Ifex
BBaxter Healthcare Corporation
Phase 3
Purinethol
SStason
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Tropical Spastic Paraparesis1 trial
Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis
Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 1·NCT00076843·9 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Hu-Mik- Beta-1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- NNational Cancer Institute (NCI)